Pharmaceuticals
The latest news about Pharmaceuticals: headlines, AI summaries and the full story from every source.
- China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
- Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Development
- Amarin Returns to Profitability in Q3 Following Corporate Restructuring
- Liquidia Corporation Upgraded to Strong Buy by Raymond James
- FDA Approves Bayer's Asundexian for Secondary Stroke Prevention
- Ionis Reports Q3 2026 Revenue Growth Driven by DAWNZERA Amid TRYNGOLZA Launch Adjustments
- US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
- Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug
- Novo Nordisk Reports Strong Third Quarter Results Driven by Oral Wegovy Growth
- Healthcare Sector Reports Strong Earnings Performance with 96% EPS Beat Rate
- Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
- Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
- Teva Pharmaceuticals Reports Improved Margins and Growth in Branded Therapies
- Pomerantz Law Firm Files Class Action Lawsuit Against Tenax Therapeutics Following Clinical Trial Failure
- Novo Nordisk Raises Full-Year Guidance Following Strong Q3 Patient Growth and Pipeline Progress
- Rhythm Pharmaceuticals Shares Surge Following Report of AstraZeneca Acquisition Bid
- AbbVie and Nxera Pharma Enter $1.5 Billion Licensing Agreement for IBD Therapy
- Axsome Therapeutics Reports 52% Revenue Growth Driven by Auvelity Sales
- United Therapeutics Acquires Pfizer Royalty Interest in Experimental Lung Therapy Ralinepag
- BioCryst Pharmaceuticals Reports Q3 Earnings Beat on Strong Revenue Growth
- Novo Nordisk Raises Annual Outlook Amid Strong Demand for Wegovy and Ozempic
- Novo Nordisk Raises Full-Year Outlook Following Strong Wegovy Sales
- Pfizer Raises 2026 Revenue and EPS Guidance Amid Strong Product Growth
- Compass Pathways to Submit FDA New Drug Application for COMP360 Within Two Weeks
- Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth
- Madrigal Pharmaceuticals Announces Q3 Sales Growth and Updates Clinical Trial Timelines
- Alkermes Reports Q3 2026 Results with Strong Proprietary Product Growth
- Pfizer Reports Q3 2026 Results with Increased Full-Year Guidance Amid Non-COVID Growth
- Biodexa Pharmaceuticals and SXT Pharmaceuticals Lead Short Interest Among Sub-$2B Healthcare Stocks
- Pfizer Reports Flat Third-Quarter Revenue and Raises Full-Year Guidance
- Pfizer Raises Annual Profit and Revenue Forecasts Driven by Eliquis Demand
- Pfizer Raises Full-Year Guidance and Appoints Cecile Guegan as CFO
- Vertex Pharmaceuticals Issues 2026 Revenue Guidance of $13.15B-$13.25B
- Neurocrine Biosciences Reports Q3 2026 Record Revenue and Raised INGREZZA Guidance
- Neurocrine Biosciences Reports Q3 Earnings Beat and Raises Ingrezza Sales Guidance
- Eli Lilly Reports Strong Third Quarter Results Driven by GLP-1 Growth and Raises Full-Year Guidance
- Truist Downgrades Alnylam Pharmaceuticals to Hold Due to Amvuttra Sales Uncertainty
- AbbVie Reports Strong Third Quarter Growth Driven by Skyrizi and Rinvoq
- Merck Shares Rise Following Strong Third-Quarter Earnings and Analyst Upgrades
- AbbVie Reports Strong Q3 2026 Results Driven by Skyrizi and Rinvoq Growth
- Regeneron Pharmaceuticals Shares Reach 52-Week High Following Strong Q3 Results
- Deutsche Bank Downgrades Novartis to Sell Following Mixed Q3 Results
- Ultragenyx Receives Conditional UK Marketing Authorization for Dojolvi
- Oppenheimer Upgrades Incyte to Outperform Amid Growth Potential Beyond Jakafi
- Supernus Pharmaceuticals Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
- Teva Pharmaceutical Industries Pivot to Branded Drugs Drives Significant Stock Growth
- BridgeBio Pharma Reports Strong Q3 2026 Revenue Growth Driven by Attruby Expansion
- AbbVie Reports Q3 Earnings Beat Driven by Skyrizi and Rinvoq Growth
- AbbVie Reports Q3 2026 Revenue Beat Driven by Skyrizi and Rinvoq Growth
- AbbVie Exceeds Q3 Earnings and Revenue Expectations, Raises Full-Year Guidance